-
Esketamine, sold
under the
brand names Spravato (for depression) and
Ketanest (for anesthesia)
among others, is the S(+)
enantiomer of ketamine. It is...
-
ketamine –
esketamine commercially sold as
Spravato – was
approved as an
antidepressant by the
European Medicines Agency in 2019.
Esketamine was approved...
- the (R)-(−)
enantiomer of ketamine.
Similarly to
racemic ketamine and
esketamine, the S(+)
enantiomer of ketamine,
arketamine is
biologically active; however...
- an
atypical agent in that it
appears not to do this. In
August 2020,
esketamine (JNJ-54135419) was
approved by the U.S. Food and Drug
Administration (FDA)...
-
stereoisomer of
ketamine is
known as
esketamine, and this is its
BANTooltip British Approved Name
while esketamine hydrochloride is its
BANMTooltip British...
-
receptor positive allosteric modulator –
approved for
postpartum depression Esketamine (Spravato) – non-competitive NMDA
receptor antagonist,
other actions Gepirone...
- of ketamine, but
appear to be as
effective as
esketamine in its
potency and duration.
Unlike esketamine, (S)-norketamine does not
appear to significantly...
-
March 2019, the Food and Drug
Administration approved Janssen's
Spravato (
esketamine nasal spray) for treatment-resistant
major depressive disorder. This marked...
-
being developed to
prolong the
antidepressant effects of
ketamine and
esketamine, by 2 to 3 times, from 2 to 7 days to 14 days in
terms of preliminary...
- disorder, and
major depressive disorder. Spravato, a
nasal spray form of
esketamine, was
approved by the FDA in 2019 for use in treatment-resistant depression...
